New scan could reveal hidden prostate cancer
NCT ID NCT03181867
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study tests a radioactive tracer called 18F-DCFPyL to see if it can better detect prostate cancer that has spread outside the prostate or come back after treatment. About 360 men with high-risk or recurrent prostate cancer will get an injection of the tracer and then have a PET/CT scan. The goal is to improve imaging accuracy so doctors can make better treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-DCFPyL (a radioactive tracer for PET/CT scans)
What this could lead to
If successful, this could lead to a more accurate imaging method to find where prostate cancer has spread or returned, helping doctors choose the right treatment.
What could go wrong
This is a Phase 2 trial with 360 participants, so results are still early. The tracer may not detect all cancer sites, and its benefit over current scans is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.